SCHEMBL5607545

SCHEMBL5607545

Oc1cc(F)ccc1Oc1ccc(Cl)cc1-c1nn[nH]n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.60
CASP6 P55212 1/20 0.44
KDM1A O60341 1/20 0.43
TTR P02766 2/20 0.42
NR1I2 O75469 1/20 0.42
LMNA P02545 1/20 0.42
PGR P06401 1/20 0.42
HSP90AA1 P07900 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
MAPT P10636 1/20 0.42
HSPA5 P11021 1/20 0.42
HPGD P15428 1/20 0.42
CBR1 P16152 1/20 0.42
TBXA2R P21731 1/20 0.42
SLC6A2 P23975 1/20 0.42
AGTR1 P30556 1/20 0.42
SLC6A3 Q01959 1/20 0.42
GRIK1 P39086 4/20 0.42
GRIA2 P42262 4/20 0.42
SCN9A Q15858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5607916 0.91 IDO1 (0.68) IDO1TTRNR1I2LMNAPGR
SCHEMBL5607418 0.87 IDO1 (0.59) IDO1TTRNR1I2LMNAPGR
SCHEMBL5607474 0.87 CASP6 (0.53) IDO1CASP6SCN9AKDM4EPKM
SCHEMBL5613841 0.79 TTR (0.41) IDO1TTRNR1I2LMNAPGR
SCHEMBL14556369 0.79 IDO1 (0.58) IDO1TTRNR1I2LMNAPGR
SCHEMBL5607560 0.77 CASP6 (0.44) IDO1CASP6TTRNR1I2LMNA
SCHEMBL12467263 0.75 IDO1 (0.78) IDO1GRIK1KDM4ERPA1GPR35
SCHEMBL5607371 0.74 KDM4E (0.52) IDO1NR1I2KDM4EPKM
SCHEMBL5606179 0.74 MEN1 (0.59) IDO1CASP6GRIK1GRIA2KDM4E
SCHEMBL5606475 0.72 TTR (0.44) TTRNR1I2LMNAPGRHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP claimed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US claimed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO claimed
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP disclosed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US disclosed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents TYR, NFE2L2, CYP1A1 IDO1 1513/4885CASP6 735/4885KDM1A 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.